Sooji Lee Rugh, MD
Obesity Medicine · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rugh’s office at (650) 396-8080 to ask if they take your plan before you enroll.
California Medical Board record
Licence G75443 · Current
Licensed to practise in California · since 2007 · expires 2027-10-31 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Money from drug and device companies
$122 in 2025
| 2025 | 1 | 1 | None | $122 |
| 2024 | 1 | 1 | None | $130 |
| 2023 | 1 | 1 | None | $139 |
| 2020 | 1 | 1 | None | $125 |
| 2019 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Yeztugo | $122 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-08-14 | Yeztugo | $122 |
See earlier years (2024, 2023, 2020, 2019)
2024: $130
| Galderma Laboratories L.P. | None | $130 | 1 payment
|
2023: $139
| Genzyme | Dupixent | $139 | 1 payment
|
2020: $125
| Allergan | None | $125 | 1 payment
|
2019: $125
| Teva Pharmaceuticals USA | Ajovy | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · A Study To Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2dm · 2025 | Their institution | $203,631 |
| Amgen Inc. · Ph2b Type 2 Diabetes · 2024 | Their institution | $7,693 |
Professional record
- NPI
- 1770799538
- Licence
- CA G 75443California G75443: Current · expires 2027-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RB0002X (207RB0002X); Internal medicine (207R00000X)
- Mailing address
- 3039 Alameda De Las Pulgas, Menlo Park, CA, 94025
- NPI first listed
- 2007-05-15
- NPI last updated
- 2011-12-07
This is when the NPI record was last certified, not a medical board exam.